Cantor Fitzgerald analyst Li Watsek initiated coverage of Ideaya Biosciences with an Overweight rating.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences management to meet with Oppenheimer
- Ideaya Biosciences announces inducement grants under Nasdaq listing rule
- Ideaya Biosciences price target lowered to $52 from $54 at Wedbush
- Ideaya Biosciences should be bought on weakness, says Citi
- Ideaya Biosciences price target raised to $48 from $47 at Goldman Sachs